Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ear cartilage injection may offer longer knee pain relief than PRP

NCT ID NCT07453953

Disease control Sponsor: Taichung Veterans General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a single injection of Mytocel MSK (made from a patient's own ear cartilage) can improve knee osteoarthritis better than standard PRP injections. Thirty adults with mild-to-moderate knee arthritis will receive either the new cell therapy or PRP. Researchers will track pain, function, and cartilage changes over 52 weeks using questionnaires and MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mytocel MSK with AMT (autologous micrograft from ear cartilage)
What this could lead to
If it works, this could offer a longer-lasting, single-injection treatment for knee osteoarthritis, reducing pain and improving joint function.
What could go wrong
This is a very early (Phase 1) trial with only 30 participants, so results may not be generalizable. The procedure involves harvesting ear cartilage, which carries minor surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 18 years or older * Radiographic diagnosis of knee osteoarthritis with Kellgren-Lawrence (KL) grade 1 to 3 * Ability and willingness to provide written informed consent Exclusion Criteria: * Diagnosis of rheumatoid arthritis * Advanced knee osteoarthritis requiring total knee arthroplasty * Diagnosis of autoimmune disease * Severe meniscal tear or ligament injury requiring surgical intervention * Body mass index (BMI) greater than 30 kg/m² * Platelet count less than 100,000 per microliter * Severe genu varum or genu valgum deformity * Intra-articular corticosteroid injection within 3 months prior to screening * Intra-articular hyaluronic acid injection within 6 months prior to screening * Pregnant or breastfeeding women * Known human immunodeficiency virus (HIV) infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mytocel MSK with amt

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.